Calvenza EIV/EHV (Canada)This page contains information on Calvenza EIV/EHV for veterinary use.
The information provided typically includes the following:
- Calvenza EIV/EHV Indications
- Warnings and cautions for Calvenza EIV/EHV
- Direction and dosage information for Calvenza EIV/EHV
Calvenza EIV/EHVThis treatment applies to the following species:
Equine Rhinopneumonitis-Influenza Vaccine
Veterinary Use Only
Calvenza EIV/EHV Indications
For the vaccination of healthy, susceptible horses 6 months of age or older, including pregnant mares, as an aid in the reduction of respiratory diseases caused by equine herpesvirus type 1 (EHV-1) and type 4 (EHV-4), and by equine influenza virus types A2 North American and A2 Eurasian.
Administration and Dosage: Shake well before use. Using aseptic technique, vaccinate horses intramuscularly with a 2 mL dose. Administer a second 2 mL dose intramuscularly in 3-4 weeks using a different injection site. Administer a third 2 mL dose in 3-4 weeks by either the intramuscular or intranasal route.
PrecautionsStore at 2-7°C. Do not freeze. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Anaphylactoid reactions may occur. Antidote: Epinephrine.
Preservatives: Gentamicin and thimerosal.
Manufactured by: Boehringer Ingelheim Vetmedica, Inc., St. Joseph, Missouri 64506 U.S.A.
US Vet. Lic. No. 124
Manufactured for: Boehringer Ingelheim (Canada) Ltd., Burlington, Ontario L7L 5H4
2 mL syringe
10 Doses/20 mL
NAC No.: 12300455
5180 SOUTH SERVICE ROAD, BURLINGTON, ON, L7L 5H4
|Customer Care No.:||800-567-1885|
|Technical Services No.:||1-877-565-5501|
|Every effort has been made to ensure the accuracy of the Calvenza EIV/EHV information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-02-06